Thermo Fisher Scientific Inc
corporate.thermofisher.comWhat Do They Do?
Sells laboratory supplies, diagnostic products and outsourced drug-development services to pharmaceutical and biotech companies, healthcare laboratories, and academic and government institutions.
10-K for FY2025, filed Feb 26, 2026Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of…View ↗
Our laboratory products include lab consumables, equipment and chemicals that are used for life science research and drug discovery and…View ↗
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products…View ↗
How Do They Make Money?
-
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗
$44.6B
-
10-K for FY2025, filed Feb 26, 2026
$44.6B ↗
| Segment | Share | Revenue |
|---|---|---|
|
Consumables
|
42%
FY2022: 46%
|
Consumables, FY2025
$18.7B Sources
|
|
Instruments
|
16%
FY2022: 18%
|
Instruments, FY2025
$7.3B Sources
|
|
Service revenues
|
42%
FY2022: 36%
|
Service revenues, FY2025
$18.6B Sources
|
Who Are Their Customers?
Sells to pharmaceutical and biotech companies, academic and government researchers, and healthcare, industrial and research labs through its direct sales force, online commerce and third-party distributors.
10-K for FY2025, filed Feb 26, 2026Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world…View ↗
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and…View ↗
Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of…View ↗
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products…View ↗
Do Revenues Turn Into Profits?
Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 14 cents into free cash flow.
10-K for FY2025, filed Feb 26, 2026
$7.7BView ↗
10-K for FY2025, filed Feb 26, 2026
$6.7BView ↗
10-K for FY2025, filed Feb 26, 2026
$6.3BView ↗
How Are They Changing?
-
Mar 24, 2026
Completed acquisition of Clario Holdings
Sources
8-K, filed Mar 24, 2026
On March 24, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of…View ↗
Growing. Revenue grew 14% in 4 years, from $39.2B in FY2021 to $44.6B in FY2025, about 3% a year.
Proteomic solutions
The latest report describes genetic-sciences solutions as supporting both genomic and proteomic decisions, while the older report describes genomic solutions.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in…View ↗
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in…View ↗
Loading...
